Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2016

01-05-2016 | Original Article

Breast sentinel lymph node navigation with three-dimensional computed tomography–lymphography: a 12-year study

Authors: Shigeru Yamamoto, Kazuyoshi Suga, Kazunari Maeda, Noriko Maeda, Kiyoshi Yoshimura, Masaaki Oka

Published in: Breast Cancer | Issue 3/2016

Login to get access

Abstract

Purpose

To evaluate the utility of three-dimensional (3D) computed tomography (CT)−lymphography (LG) breast sentinel lymph node navigation in our institute.

Patients and methods

Between 2002 and 2013, we preoperatively identified sentinel lymph nodes (SLNs) in 576 clinically node-negative breast cancer patients with T1 and T2 breast cancer using 3D CT–LG method. SLN biopsy (SLNB) was performed in 557 of 576 patients using both the images of 3D CT–LG for guidance and the blue dye method.

Results

Using 3D CT–LG, SLNs were visualized in 569 (99 %) of 576 patients. Of 569 patients, both lymphatic draining ducts and SLNs from the peritumoral and periareolar areas were visualized in 549 (96 %) patients. Only SLNs without lymphatic draining ducts were visualized in 20 patients. Drainage lymphatic pathways visualized with 3D CT–LG (549 cases) were classified into four patterns: single route/single SLN (355 cases, 65 %), multiple routes/single SLN (59 cases, 11 %) single route/multiple SLNs (62 cases, 11 %) and multiple routes/multiple SLNs (73 cases, 13 %). SLNs were detected in 556 (99.8 %) of 557 patients during SLNB.

Conclusion

CT–LG is useful for preoperative visualization of SLNs and breast lymphatic draining routes. This preoperative method should contribute greatly to the easy detection of SLNs during SLNB.
Literature
1.
Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349:1864–7.CrossRefPubMed
2.
Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462–8.CrossRefPubMedPubMedCentral
3.
Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.CrossRefPubMedPubMedCentral
4.
Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32:1365–83.CrossRefPubMed
5.
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.CrossRefPubMed
6.
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305.CrossRefPubMedPubMedCentral
7.
Suga K, Ogasawara N, Yuan Y, Okada M, Matsunaga N, Tangoku A. Visualization of breast lymphatic pathways with an indirect CT lymphography using a nonionic monometric contrast medium iopamidol: preliminary results. Invest Radiol. 2003;38:73–84.CrossRefPubMed
8.
Tangoku A, Yamamoto S, Suga K, Ueda K, Nagashima Y, Hida M, et al. Sentinel lymph node biopsy using computed tomography–lymphography in patients with breast cancer. Surgery. 2004;135:258–65.CrossRefPubMed
9.
Suga K, Yamamoto S, Tangoku A, Oka M, Kawakami Y, Matsunaga N. Breast sentinel lymph node navigation with three-dimensional interstitial multidetector-row computed tomographic lymphography. Invest Radiol. 2005;40:336–42.CrossRefPubMed
10.
Yamamoto S, Maeda N, Tamesa M, Nagashima Y, Suga K, Oka M. Sentinel lymph node detection in breast cancer patients by real-time virtual sonography constructed with three-dimensional computed tomography–lymphography. Breast J. 2010;16:4–8.CrossRefPubMed
11.
Yamamoto S, Maeda N, Tamesa M, Nagashima Y, Yoshimura K, Oka M. Prospective ultrasonographic prediction of sentinel lymph node metastasis by real-time virtual sonography constructed with three-dimensional computed tomography–lymphography in breast cancer patients. Breast Cancer. 2012;19:77–82.CrossRefPubMed
12.
Yamamoto S, Maeda N, Yoshimura K, Oka M. Intraoperative detection of sentinel lymph nodes in breast cancer patients using ultrasonography-guided direct indocyanine green dye-marking by real-time virtual sonography constructed with three-dimensional computed tomography–lymphography. Breast. 2013;22:933–7.CrossRefPubMed
13.
Cody HS 3rd. Sentinal lymph node mapping in breast cancer. Breast Cancer. 1999;25:13–22.CrossRef
14.
Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106:4–16.CrossRefPubMed
15.
Iwasaki T, Mikami E, Shimosegawa T, Arai O, Mitake T (2004) Real-time virtual sonography: a novel navigation tool in percutaneous radiofrequency ablation of hepatocellular carcinomas. In: Radiological Society of North America scientific assembly and annual meeting program. Oak Brook: Radiological Society of North America, p 392.
16.
Nakano S, Yoshida M, Fujii K, Yorozuya K, Mouri Y, Kousaka J, et al. Fusion of MRI and sonography image for breast cancer evaluation using real-time virtual sonography with magnetic navigation: first experience. Jpn J Clin Oncol. 2009;39:552–9.CrossRefPubMed
17.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61.CrossRefPubMedPubMedCentral
18.
Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–18.CrossRefPubMed
19.
Postma EL, van Wieringen S, Hobbelink MG, Verkooijen HM, van den Bongard HJ, Borel Rinkes IH, et al. Sentinel lymph node biopsy of the internal mammary chain in breast cancer. Breast Cancer Res Treat. 2012;134:735–41.CrossRefPubMedPubMedCentral
20.
Heuts EM, van der Ent FW, von Meyenfeldt MF, Voogd AC. Internal mammary lymph drainage and sentinel node biopsy in breast cancer: a study on 1008 patients. Eur J Surg Oncol. 2009;35:252–7.CrossRefPubMed
21.
Qiu PF, Liu JJ, Liu YB, Yang GR, Sun X, Wang YS. A modified technology could significantly improve the visualization rate of the internal mammary sentinel lymph nodes in breast cancer patients. Breast Cancer Res Treat. 2012;136:319–21.CrossRefPubMed
22.
Shimazu K, Tamaki Y, Taguchi T, Motomura K, Inaji H, Koyama H, et al. Lymphoscintigraphic visualization of internal mammary nodes with subtumoral injection of radiocolloid in patients with breast cancer. Ann Surg. 2003;237:390–8.PubMedPubMedCentral
23.
Motomura K, Sumino H, Noguchi A, Horinouchi T, Nakanishi K. Sentinel nodes identified by computed tomography–lymphography accurately stage the axilla in patients with breast cancer. BMC Med Imaging. 2013;9(13):42.CrossRef
24.
Yokohata K, Hattori M, Fujimoto T, Chikazawa N, Maeyama R, Yamanaka N, et al. Computed tomographic lymphography predicts the difficulty of sentinel lymph node biopsy with dye. Breast Cancer. 2014;21:198–201.CrossRefPubMed
25.
Tan H, Yang B, Wu J, Wana S, Gu Y, Li W, et al. Localization and evaluation of sentinel lymph node in breast cancer from computed tomographic lymphography. J Comput Assist Tomogr. 2011;35:367–74.CrossRefPubMed
26.
Minohata J, Takao S, Hirokaga K. Sentinel lymph node biopsy using CT lymphography in breast cancer. Breast Cancer. 2011;18:129–36.CrossRefPubMed
27.
Yamashita K, Shimizu K. Video-assisted breast surgery can sample the second and third sentinel nodes to omit axillary node dissection for sentinel-node-positive patients. Surg Endosc. 2009;23:1574–80.CrossRefPubMed
28.
Takahashi M, Sasa M, Hirose C, Hisaoka S, Taki M, Hirose T, et al. Clinical efficacy and problems with CT lymphography in identifying the sentinel node in breast cancer. World J Surg Oncol. 2008;12(6):57.CrossRef
29.
Yamashita K, Shimizu K. Video-assisted breast surgery and sentinel lymph node biopsy guided by three-dimensional computed tomographic lymphography. Surg Endosc. 2008;22:392–7.CrossRefPubMed
30.
Minato M, Hirose C, Sasa M, Nishitani H, Hirose Y, Morimoto T. 3-dimensional computed tomography lymphography-guided identification of sentinel lymph nodes in breast cancer patients using subcutaneous injection of nonionic contrast medium: a clinical trial. J Comput Assist Tomogr. 2004;28:46–51.CrossRefPubMed
31.
Yamashita K, Shimizu K. Evaluation of sentinel lymph node metastasis alone guided by three-dimensional computed tomographic lymphography in video-assisted breast surgery. Surg Endosc. 2009;23:633–40.CrossRefPubMed
32.
Kitai T, Inomoto T, Miwa M, Shikayama T. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer. 2005;12:211–5.CrossRefPubMed
33.
Sugie T, Sawada T, Tagaya N, Kinoshita T, Yamagami K, Suwa H, et al. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer. Ann Surg Oncol. 2013;20:2213–8.CrossRefPubMed
34.
Kitai T, Kawashima M. Transcutaneous detection and direct approach to the sentinel node using axillary compression technique in ICG fluorescence-navigated sentinel node biopsy for breast cancer. Breast Cancer. 2012;19:343–8.CrossRefPubMed
Metadata
Title
Breast sentinel lymph node navigation with three-dimensional computed tomography–lymphography: a 12-year study
Authors
Shigeru Yamamoto
Kazuyoshi Suga
Kazunari Maeda
Noriko Maeda
Kiyoshi Yoshimura
Masaaki Oka
Publication date
01-05-2016
Publisher
Springer Japan
Published in
Breast Cancer / Issue 3/2016
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-015-0584-0

Other articles of this Issue 3/2016

Breast Cancer 3/2016 Go to the issue

Special Feature

The Japanese Breast Cancer Society clinical practice guideline for surgical treatment of breast cancer, 2015 edition

Special Feature

The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2015 edition

Original Article

Assessment of axillary lymph nodes in patients with breast cancer with diffusion-weighted MR imaging in combination with routine and dynamic contrast MR imaging

Original Article

Production and characterization of a novel long-acting Herceptin-targeted nanobubble contrast agent specific for Her-2-positive breast cancers

Original Article

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer

Original Article

The association of cognitive fatigue with menopause, depressive symptoms, and quality of life in ambulatory breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits